Últimas noticias sobre Intelligent Living (NASDAQ:ILAG) Bolsa

Intelligent Living

Intelligent Living Application Group Inc is engaged in the business of manufacturing and selling mechanical locksets. The business is spread across the Unites States, Canada, Australia, and China. Majority of the revenue is generated from the United States.

Intelligent Living Application Group Inc. - Ordinary Shares

Intelligent Living Application Group Inc

Community Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHCT#NYSE">CHCT</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.47 by 17.02 percent. This is a 6.78 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $30.08 million which beat the analyst consensus estimate of $29.64 million by 1.47 percent. This is a 2.54 percent increase over sales of $29.33 million the same period last year.

Earnings

Earnings Beats

News

CHCT

Community Healthcare Q1 FFO $0.55 Beats $0.47 Estimate, Sales $30.08M Beat $29.64M Estimate

Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) reported quarterly earnings of $2.98 per share which beat the analyst consensus estimate of $2.76 by 7.97 percent. This is a 56.02 percent increase over earnings of $1.91 per share from the same period last year. The company reported quarterly sales of $745.54 million which beat the analyst consensus estimate of $734.14 million by 1.55 percent. This is a 22.24 percent increase over sales of $609.89 million the same period last year.

ENVA

Enova International Q1 Adj. EPS $2.98 Beats $2.76 Estimate, Sales $745.54M Beat $734.14M Estimate

Diamond Hill Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHIL#NASDAQ">DHIL</a>) reported quarterly earnings of $3.77 per share. This is a 25.67 percent increase over earnings of $3.00 per share from the same period last year. The company reported $37.12 million in sales this quarter. This is a 2.26 percent increase over sales of $36.29 million the same period last year.

DHIL

Diamond Hill Investment Q1 EPS $3.77 Up From $3.00 YoY, Sales $37.12M Up From $36.29M YoY

Sonoco Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>) reported quarterly earnings of $1.38 per share which missed the analyst consensus estimate of $1.42 by 2.82 percent. This is a 23.21 percent increase over earnings of $1.12 per share from the same period last year. The company reported quarterly sales of $1.71 billion which missed the analyst consensus estimate of $2.02 billion by 15.30 percent. This is a 30.56 percent increase over sales of $1.31 billion the same period last year.

Earnings Misses

Sonoco Prods Q1 Adj. EPS $1.38 Misses $1.42 Estimate, Sales $1.71B Miss $2.02B Estimate

Mirion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) affirms FY2025 Adj EPS guidance from $0.45-$0.50 to $0.45-$0.50 vs $0.46 analyst estimate. Raises FY2025 sales outlook from $895.23 million-$912.45 million to $903.84 million-$921.06 million vs $904.18 million estimate.

Guidance

Mirion Technologies Affirms FY2025 Adj EPS Guidance of $0.45-$0.50 vs $0.46 Est; Raises FY2025 Sales Guidance from $895.23M-$912.45M to $903.84M-$921.06M vs $904.18M Est

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day
Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted cancers and in combination with market leading therapies to overcome resistance in NSCLC
Nuvectis Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology today provided poster presentation highlights for NXP900 from the 2025 American Association for Cancer Research Meeting (2025 AACR). These posters highlight key data supporting the rationale for the Phase 1b program in biomarker-selected cancers as a single agent, and in combination with market leading therapies to overcome treatment resistance in non-small cell lung cancer (NSCLC). The posters are available on the Company's website.
NXP900 Phase 1a highlights
<ul>
<li>Twenty-nine patients with advanced cancers (not selected for target biomarkers, i.e., "all comers") were treated with single agent NXP900 at doses ranging from 20 to 250 mg/day. In these patients, the median age was 62 years (range: 36-89), 62% were males, 83% had an ECOG performance score of 1, and the median number of prior therapies was 5.</li>
<li>The most common treatment emergent adverse events were fatigue, diarrhea, nausea, abdominal pain, dyspnea and vomiting, mostly reported as Grade 1-2. The dose limiting toxicity (DLT) dose level has not been identified in doses up to 250 mg/day.</li>
<li>Systemic exposure increased with increased doses of NXP900, achieving clinically relevant concentrations starting at the 150 mg/day dose, as demonstrated by a robust pharmacodynamic response. Maximal level of SRC inhibition in patient samples after a single dose of NXP900 exceeded 90%.</li>
</ul>
Three preclinical posters highlight potential use of NXP900 in NSCLC
<ul>
<li>As a single agent, NXP900 potently inhibited YAP1 nuclear localization and the proliferation of YES1/YAP1-amplified NSCLC cells in vitro and induced substantial tumor growth inhibition in an in vivo model of YES1-amplified NSCLC. Together, these are the data that demonstrate the relevance of inhibiting NXP900's direct target, the SRC kinase family member YES1, in NSCLC, and provide the rationale to target NSCLC and potentially other cancers with Hippo pathway inactivating alterations (YAP1, FAT1, NF2, TAZ).</li>
<li>As a combination partner, the addition of NXP900 to market leading epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) kinase inhibitors resulted in reversal of resistance to the anti-EGFR and anti-ALK agents, providing the scientific rationale for the clinical development of NXP900 in these settings, as acquired resistance remains an unmet clinical need in NSCLC.</li>
</ul>
Phase 1b program
The Phase 1b portion of the single agent study is expected to commence shortly after the conclusion of the dose escalation phase, in which patients with advanced cancers with YES1 gene amplifications and hippo pathway alterations will be included. Another objective of the Phase 1b program is to evaluate NXP900 in combination with existing market-leading therapies for the treatment of resistant NSCLC.
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis commented, "This year's AACR presentations mark an important milestone in the development of NXP900. As new preclinical data continue to unlock the unique potential of NXP900 as a single agent and as a combination partner, we revealed, for the first time, preliminary clinical data from the ongoing Phase 1a dose escalation clinical trial that provide a link between the existing preclinical mechanistic data and NXP900's potential in the clinic." Mr. Bentsur concluded, "with the ability to induce a robust pharmacodynamic response and an acceptable safety profile, we believe that the therapeutic window of NXP900 puts it in a favorable position to demonstrate clinical efficacy in target patients, which is the primary objective of the Phase 1b program that will commence in the coming months. We are excited about the potential of NXP900 as its clinical profile continues to evolve."

Biotech

General

NVCT

Nuvectis Pharma Unveils Poster Presentation Highlights For NXP900 From The 2025 American Association For Cancer Research Meeting Including Phase 1a Dose-Escalation  Update For Treatment With NXP900

Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) has outperformed the market over the past 5 years by 32.45% on an annualized basis producing an average annual return of 46.8%. Currently, Vistra has a market capitalization of $43.99 billion. 
Buying $100 In VST: If an investor had bought $100 of VST stock 5 years ago, it would be worth $668.37 today based on a price of $129.33 for VST at the time of writing.
<h3>Vistra's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745958614_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Vistra 5 Years Ago Would Be Worth Today

Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) raises FY2025 FFO guidance from $3.26-$3.44 to $3.31-$3.47 vs $3.37 analyst estimate..

Highwoods Props Raises FY2025 FFO Guidance from $3.26-$3.44 to $3.31-$3.47 vs $3.37 Est

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed up 64.85% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 46.60% at $0.11</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 26.87% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 26.58% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 15.48% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 10.34% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed up 8.64% at $4.65</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 8.30% at $0.84</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed up 7.65% at $9.68</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 6.00% at $0.11</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 5.81% at $5.89</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 4.72% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed up 4.35% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 3.85% at $1.46</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 3.68% at $0.21</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 3.60% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 3.45% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 3.33% at $0.01</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 30.83% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 26.83% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 9.09% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 8.54% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 4.83% at $1.11</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed down 4.30% at $0.43</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BLGVF

BLOZF

CNBX

CPHRF

CRLBF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CWBHF

ELLXF

FFNTF

GBHPF

GNLN

GRWG

GTBIF

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

MGWFF

MRMD

NWVCF

OILFF

RMHB

SOLCF

TCNNF

TGIFF

Bullish Sentiment Across The Cannabis Space - Check Full Movers For April 29, 2025

WIIM

KFRC

KFRC stock has given up its prior loss. Kforce shares were trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 EPS guidance below estimates.

Rosenblatt analyst Barton Crockett initiated coverage on The Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) on Tuesday with a Buy rating and a <a href="https://www.benzinga.com/quote/TTD/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $77</a>.
Crockett launched coverage of the Trade Desk as a key pillar of his initiation of DSPs and SSPs in AdTech.
The analyst noted that the Trade Desk, as the leading DSP, has appealing exposure to the secularly constructive growth of CTV and programmatic and the expansion of the open Internet.
Also Read: <a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture" target="_blank" rel="noreferrer noopener">Jim Cramer Says Trade Desk Needs to Answer Tough Questions as Stock Struggles</a>
The main issue right now is macro concerns prompted by Trump&#8217;s tariff wars.
For Trade Desk, there are also nascent concerns about rising competition from Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and execution issues on the rollout of a new Kokai version of its core ad buying platform.
However, Crockett expects policy pressures from Trump to abate ahead of the midterms.
The analyst noted that Amazon&#8217;s competition will prove navigable. He also said Kokai interface issues are addressable. Crockett also emphasized the potential for upside from the recent AdTech antitrust decision against Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google.
Trade Desk shares over the past two years have traded in an elevated EV/EBITDA range of over 40 to 50 times. However, the stock dropped 33% to $81.92 the day after reporting fourth-quarter of 2024 results on Feb. 12 and has slid more since then to a recent close near $54, and a 55% drop over the last 3 months. 
The proximate cause was a moderate miss versus the fourth quarter of 2024 guidance, its first in 33 quarters as a public company, and somewhat light guidance for the first quarter of 2025 and 2025. But consensus estimates, which Crockett noted as reasonable given the macro ends up being OK, appear to be in a decent place, at a 12% and 13% trim to adjusted EBITDA from before and ~+10% and ~+25% Y/Y growth in 2025 and 2026, respectively.
The stock slide has compressed the multiple more than half to an EV of 21.5 times 2025 adjusted EBITDA.
The analyst noted that the Trade Desk&#8217;s multiple can recover somewhat in a better environment.
Trade Desk remains a direct and leading participant in the strong and accelerating secular trend toward streaming TV viewership, which is driving TV advertising towards Connected TV and programmatic. Streaming viewership on TVs increased by 9% on average year-over-year (Y/Y) in the first nine months of 2024, rising to an average of 16% growth in the last six months, ending in March.
Programmatic ad growth in the US averaged +25% from 2020 to 2022, slowed to +4 % in 2023, and rebounded to +18% in 2024 (IAB/PwC). CTV ad growth in the US averaged +18% from 2022 to 2024 and is seen up in the mid-teens in 2025 by the IAB/PwC.
Trade Desk, the most extensive independent DSP, with $12 billion of gross spending in 2024, has a history of participating in this secular growth, with Crockett estimates that gross spending increased an average of 23% year over year from 2021 to 2024.
Crockett projected first-quarter revenue of $578.7 million and EPS of $0.25.
Price Action: TTD stock is up 0.5% to $54.67 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44848020/google-genai-ai-cloud-services-drive-analyst-confidence-in-long-term-growth" target="_blank" rel="noreferrer noopener">Google GenAI, AI Cloud Services Drive Analyst Confidence In Long-Term Growth</a></li>
</ul>
Photo: Shutterstock

Price Target

Initiation

Analyst Ratings

AMZN

GOOG

GOOGL

Analyst Says Trade Desk Can Shake Off Challenges, Ride Streaming's Next Big Wav

Rocky Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.52 by 40.38 percent. This is a 78.05 percent increase over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $114.07 million which beat the analyst consensus estimate of $112.65 million by 1.26 percent. This is a 1.03 percent increase over sales of $112.91 million the same period last year.

RCKY

Rocky Brands Q1 Adj. EPS $0.73 Beats $0.52 Estimate, Sales $114.07M Beat $112.65M Estimate

BKNG

Booking Holdings shares are trading lower after the company reported Q1 financial results. Additionally the stock may be moving in sympathy with Trivago, which reported Q1 financial results and missed its revenue estimate.

Mirion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.08 by 25 percent. This is a 66.67 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $202.00 million which beat the analyst consensus estimate of $200.70 million by 0.65 percent. This is a 4.88 percent increase over sales of $192.60 million the same period last year.

Mirion Technologies Q1 Adj. EPS $0.10 Beats $0.08 Estimate, Sales $202.00M Beat $200.70M Estimate

Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 67.39 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $32.51 million which beat the analyst consensus estimate of $28.87 million by 12.62 percent. This is a 27.65 percent increase over sales of $25.47 million the same period last year.

STEM

Stem Q1 GAAP EPS $(0.15) Beats $(0.18) Estimate, Sales $32.51M Beat $28.87M Estimate

Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) affirms FY2025 sales outlook from $125.00 million-$175.00 million to $125.00 million-$175.00 million vs $150.93 million estimate.

Stem Affirms FY2025 Sales Guidance of $125.00M-$175.00M vs $150.93M Est

Acadia Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKR#NYSE">AKR</a>) raises FY2025 FFO guidance from $1.30-$1.39 to $1.32-$1.39 vs $1.34 analyst estimate..

Acadia Realty Trust Raises FY2025 FFO Guidance from $1.30-$1.39 to $1.32-$1.39 vs $1.34 Est

Essex Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) is looking for Q2 FFO of $3.90-$4.02 vs $4.00 analyst estimate..

Essex Property Trust Sees Q2 FFO $3.90-$4.02 vs $4.00 Est

Essex Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) affirms FY2025 FFO guidance from $15.56-$16.06 to $15.56-$16.06 vs $15.93 analyst estimate..

Essex Property Trust Affirms FY2025 FFO Guidance of $15.56-$16.06 vs $15.93 Est

Paragon Technologies, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PGNT#OTC">PGNT</a>) ("Paragon") today announced that it has reached a settlement agreement with Hesham M. Gad with respect to the ongoing litigation and other related matters. Pursuant to the agreement, Mr. Gad has agreed to dismiss his claims against directors Samuel S. Weiser, Jack H. Jacobs, H. Timothy Eriksen, David Lontini, and Howard Brownstein, and Paragon has concurrently agreed to dismiss its counterclaims against Mr. Gad.

Comments

Intelligent Living

Noticias

Últimas noticias sobre Intelligent Living (NASDAQ:ILAG) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL